Previous research has shown that chronic obstructive pulmonary disease (COPD) is associated with eosinophilic airway inflammation in 10-20% of patients. Benralizumab, a monoclonal antibody, has been shown to decrease the number of blood and sputum eosinophils. In this trial of 101 patients with COPD whether benralizumab reduces the number of acute exacerbations was investigated. Benralizumab was found to be no more effective at preventing acute COPD exacerbations ...Monday 8 September 2014
Research Explores Use of Benralizumab for Chronic Obstructive Pulmonary Disease
Previous research has shown that chronic obstructive pulmonary disease (COPD) is associated with eosinophilic airway inflammation in 10-20% of patients. Benralizumab, a monoclonal antibody, has been shown to decrease the number of blood and sputum eosinophils. In this trial of 101 patients with COPD whether benralizumab reduces the number of acute exacerbations was investigated. Benralizumab was found to be no more effective at preventing acute COPD exacerbations ...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment